and XPEEM: a Surface-Sensitive Tool for Studying Single Particles in Li-Ion Battery Composite Electrodes.

X-ray photoemission electron microscopy (XPEEM), with its excellent spatial resolution, is a well-suited technique for elucidating the complex electrode-electrolyte interface reactions in Li-ion batteries. It provides element-specific contrast images that allows the study of the surface morphology and the identification of the various components of the composite electrode. It also enables the acquisition of local X-ray absorption spectra (XAS) on single particles of the electrode, such as the C and O K-edges to track the stability of carbonate-based electrolytes, F K-edge to study the electrolyte salt and binder stability, and the transition metal L-edges to gain insights into the oxidation/reduction processes of positive and negative active materials.

Revealing the Dual Surface Reactions on a HE-NCM Li-Ion Battery Cathode and Their Impact on the Surface Chemistry of the Counter Electrode.

The understanding of surface reactions at the electrode-electrolyte interfaces has been a longstanding challenge in Li-ion batteries. X-ray photoemission electron microscopy is used to throw light on the disputed aspects of the surface reactivity of high-energy Li-rich Li(Ni Co Mn)O (HE-NCM) cycled in an aprotic electrolyte against LiTiO (LTO). Despite the highly oxidative potential of 5.

L-propionylcarnitine effect on postexercise and postischemic hyperemia in patients affected by peripheral vascular disease.

The hemodynamic effect of L-propionylcarnitine (LPC) administered intravenously was evaluated in a double-blind, randomized, three-period crossover study in 12 men (aged sixty to seventy-five years) with Leriche-Fontaine stage II peripheral arterial disease of lower limbs. At baseline, maximum working capacity of each patient was determined by a standardized ergometric test. This test was repeated at 80% of each patient's maximum working capacity before and after intravenous administration of LPC.

Effects of defibrotide on physical performance and hemorheologic picture in patients with peripheral arteriopathy.

In a random double-blind study versus placebo, 60 ambulatory patients with peripheral occlusive disease of the lower limbs and claudicatio intermittens (Leriche's stage 2), were treated for 60 days with defibrotide (400 mg b.i.d.